Comparison of the Efficacy and Safety of Intravitreal Conbercept with Intravitreal Ranibizumab for Treatment of Diabetic Macular Edema: A Meta-Analysis

Overview

Journal J Ophthalmol

Publisher Wiley

Specialty Ophthalmology

Date 2020 Apr 14

PMID 32280526

Citations 4

Authors

Xiaolei Sun

Jingjing Zhang

Jingyi Tian

Shijiu Chen

Fanxing Zeng

Gongqiang Yuan

Affiliations

Soon will be listed here.

Abstract

Methods: Relevant studies were identified through systemic searches of PubMed, Embase, Cochrane Library, Ovid, CNKI, and Wanfang database up to 28 February 2019. Changes in central retinal thickness (CRT) in μm and best-corrected visual acuity (BCVA) in logMAR equivalents at 1, 3, and 6 months after initial treatment were performed by pooled analysis. Adverse events (AEs) were evaluated.

Results: Eight articles involving 588 patients with DME were identified for this meta-analysis. The results showed that IVC significantly improved BCVA compared with IVR at 6 mo (SMD = -0.74 95% CI: -1.28 to -0.2; =0.029) in patients with DME. IVC was superior to IVR in reducing central retinal thickness (CRT at 1 mo ( < 0.0001), 3 mo (=0.025), and 6 mo (=0.019)) from baseline with statistical significance. For AEs, the pooled results showed that no significant difference in the risk of intraocular pressure increased (OR = 1.71; 95% CI: 0.55 to 5.25; =0.352) or conjunctival hemorrhage (OR = 0.89; 95% CI: 0.34 to 2.34; =0.65) between two groups.

Conclusions: This meta-analysis showed that IVC trended to be more effective than IVR in terms of functional and anatomic outcomes for treating DME.

Citing Articles

Pars plana vitrectomy assisted by intravitreal injection of conbercept enhances the therapeutic effect and quality of life in patients with severe proliferative diabetic retinopathy.

Wang Q, Cai H, Xu D, Cui L, Zhang Y, Chen M Am J Transl Res. 2022; 14(2):1324-1331.

PMID: 35273734 PMC: 8902581.

Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update.

Grzybowski A, Markeviciute A, Zemaitiene R J Clin Med. 2021; 10(22).

PMID: 34830582 PMC: 8619917. DOI: 10.3390/jcm10225300.

Conbercept for Treatment of Neovascular Age-Related Macular Degeneration and Visual Impairment due to Diabetic Macular Edema or Pathologic Myopia Choroidal Neovascularization: A Systematic Review and Meta-Analysis.

Zhou P, Zheng S, Wang E, Men P, Zhai S Front Pharmacol. 2021; 12:696201.

PMID: 34712132 PMC: 8546330. DOI: 10.3389/fphar.2021.696201.

Intravitreal Therapy for Diabetic Macular Edema: An Update.

Furino C, Boscia F, Reibaldi M, Alessio G J Ophthalmol. 2021; 2021:6654168.

PMID: 33688431 PMC: 7925023. DOI: 10.1155/2021/6654168.

References

Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, Girach A . Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye (Lond). 2004; 18(10):963-83. DOI: 10.1038/sj.eye.6701476. View

. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985; 103(12):1796-806. View

Chen Y, Chen P, Chen F, Chen Y, Wang J . Comparison of efficacy of intravitreal ranibizumab between non-vitrectomized and vitrectomized eyes with diabetic macular edema. Int Ophthalmol. 2017; 38(1):293-299. DOI: 10.1007/s10792-017-0462-1. View

Stewart M . A Review of Ranibizumab for the Treatment of Diabetic Retinopathy. Ophthalmol Ther. 2017; 6(1):33-47. PMC: 5449302. DOI: 10.1007/s40123-017-0083-9. View

Furlan A, Pennick V, Bombardier C, van Tulder M . 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine (Phila Pa 1976). 2009; 34(18):1929-41. DOI: 10.1097/BRS.0b013e3181b1c99f. View

Xu Y, Rong A, Bi Y, Xu W . Intravitreal Conbercept Injection with and without Grid Laser Photocoagulation in the Treatment of Diffuse Diabetic Macular Edema in Real-Life Clinical Practice. J Ophthalmol. 2016; 2016:2143082. PMC: 5061960. DOI: 10.1155/2016/2143082. View

Zhang M, Yu D, Yang C, Xia Q, Li W, Liu B . The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res. 2008; 26(1):204-10. DOI: 10.1007/s11095-008-9718-9. View

Xu Y, Rong A, Xu W, Niu Y, Wang Z . Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study. BMC Ophthalmol. 2017; 17(1):158. PMC: 6389086. DOI: 10.1186/s12886-017-0554-8. View

Iglicki M, Zur D, Busch C, Okada M, Loewenstein A . Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the 'DR-Pro-DEX Study'. Acta Diabetol. 2018; 55(6):541-547. DOI: 10.1007/s00592-018-1117-z. View

10.

Dervenis N, Mikropoulou A, Tranos P, Dervenis P . Ranibizumab in the Treatment of Diabetic Macular Edema: A Review of the Current Status, Unmet Needs, and Emerging Challenges. Adv Ther. 2017; 34(6):1270-1282. PMC: 5487872. DOI: 10.1007/s12325-017-0548-1. View

11.

Iglicki M, Zur D, Fung A, Gabrielle P, Lupidi M, Santos R . TRActional DIabetic reTInal detachment surgery with co-adjuvant intravitreal dexamethasONe implant: the TRADITION STUDY. Acta Diabetol. 2019; 56(10):1141-1147. DOI: 10.1007/s00592-019-01357-y. View

12.

Li F, Zhang L, Wang Y, Xu W, Jiao W, Ma A . One-Year Outcome of Conbercept Therapy for Diabetic Macular Edema. Curr Eye Res. 2017; 43(2):218-223. DOI: 10.1080/02713683.2017.1379542. View

13.

Roh M, Kim H, Song J, Lim J, Kwon O . Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema. Ophthalmology. 2009; 116(1):80-6. DOI: 10.1016/j.ophtha.2008.09.036. View

14.

Zhang M, Zhang J, Yan M, Li H, Yang C, Yu D . Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys. Mol Vis. 2008; 14:37-49. PMC: 2267739. View

15.

Mello Filho P, Andrade G, Maia A, Maia M, Biccas Neto L, Muralha Neto A . Effectiveness and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: A Real-World Experience. Ophthalmologica. 2018; 241(1):9-16. DOI: 10.1159/000492132. View

16.

Wells J, Glassman A, Ayala A, Jampol L, Aiello L, Antoszyk A . Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015; 372(13):1193-203. PMC: 4422053. DOI: 10.1056/NEJMoa1414264. View

17.

Tolentino M, McLeod D, Taomoto M, Otsuji T, Adamis A, Lutty G . Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol. 2002; 133(3):373-85. DOI: 10.1016/s0002-9394(01)01381-2. View

18.

Peng Y, Zhang X, Mi L, Liu B, Zuo C, Li M . Efficacy and safety of conbercept as a primary treatment for choroidal neovascularization secondary to punctate inner choroidopathy. BMC Ophthalmol. 2017; 17(1):87. PMC: 5468989. DOI: 10.1186/s12886-017-0481-8. View

19.

Iglicki M, Busch C, Zur D, Okada M, Mariussi M, Chhablani J . DEXAMETHASONE IMPLANT FOR DIABETIC MACULAR EDEMA IN NAIVE COMPARED WITH REFRACTORY EYES: The International Retina Group Real-Life 24-Month Multicenter Study. The IRGREL-DEX Study. Retina. 2018; 39(1):44-51. DOI: 10.1097/IAE.0000000000002196. View

20.

Schatz H, Madeira D, McDonald H, Johnson R . Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol. 1991; 109(11):1549-51. DOI: 10.1001/archopht.1991.01080110085041. View